Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

about

Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

Item

http://www.wikidata.org/entity/Q40124991

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

@en

type

Item

label

Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

@en

prefLabel

Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

@en

P1476

Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach.

@en

P2093

Anton Safonov

http://www.w3.org/2001/XMLSchema#string

Cary P Gross

http://www.w3.org/2001/XMLSchema#string

Christos Hatzis

http://www.w3.org/2001/XMLSchema#string

Divyansh Agarwal

http://www.w3.org/2001/XMLSchema#string

Giampaolo Bianchini

http://www.w3.org/2001/XMLSchema#string

Lajos Pusztai

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials.

One thousand health-related quality-of-life estimates.

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

Systematic overview of cost-utility assessments in oncology.

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.

Longitudinal beta regression models for analyzing health-related quality of life scores over time

Costeffectiveness of diagnostic tests.

P2888

s10549-016-3677-3

P304

223-234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-016-3677-3

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

155

http://www.w3.org/2001/XMLSchema#string

P50

Shi-Yi Wang

P577

2016-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

289970548

http://www.w3.org/2001/XMLSchema#string

P6179

1029462968

http://www.w3.org/2001/XMLSchema#string

P698

26749360

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

5990969

http://www.w3.org/2001/XMLSchema#string